JMP Securities Reiterates Market Outperform on BioAtla, Maintains $12 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Reni Benjamin has reiterated a 'Market Outperform' rating on BioAtla (NASDAQ:BCAB) and maintained a price target of $12.
December 05, 2023 | 2:17 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
JMP Securities analyst Reni Benjamin has reiterated a 'Market Outperform' rating on BioAtla and maintained a price target of $12.
The reiteration of a 'Market Outperform' rating and the maintenance of a $12 price target by a reputable analyst could lead to increased investor confidence in BioAtla, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100